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Enhanced Neutrophil Extravasation and Rapid Progression of
Proteoglycan-Induced Arthritis in TSG-6–Knockout Mice
Sa´ndor Sza´nto´, Tama´s Ba´rdos, Istva´n Ga´l, Tibor T. Glant, and Katalin Mikecz
Objective. To gain insight into the mechanisms of
the antiinflammatory effect of tumor necrosis factor 
(TNF)–induced protein 6 (Tnfip6) in arthritis, using
Tnfip6-deficient animals.
Methods. TNF-stimulated gene 6 (TSG-6) cod-
ing for Tnfip6 was disrupted. Tnfip6-deficient mice were
backcrossed into proteoglycan-induced arthritis
(PGIA)–susceptible BALB/c mice, and arthritis was
induced by systemic immunization with cartilage pro-
teoglycan (PG). Thioglycollate-induced sterile peritoni-
tis was also assessed, to monitor the early events of
neutrophil extravasation in wild-type and Tnfip6-
deficient mice in the presence or absence of treatment
with recombinant murine Tnfip6.
Results. The onset of PGIA was similar, but
progression and severity were significantly greater, in
Tnfip6-deficient mice compared with wild-type BALB/c
mice. However, this was not associated with enhanced T
or B cell responses to cartilage PGs, but rather, an early
and more extensive infiltration of the synovium with
neutrophil leukocytes was the most prominent his-
topathologic feature of PGIA in Tnfip6-deficient mice.
This was accompanied by elevated serum levels of
interleukin-6 and amyloid A, and significantly increased
activities of the enzymes plasmin, myeloperoxidase, and
neutrophil elastase in the inflamed paw joints of Tnfip6-
null mice, when compared with that of the wild-type
littermates. Loss of control over several components of
inflammation resulted in extensive and rapid cartilage
degradation, bone erosion, joint ankylosis, and deformi-
ties in Tnfip6-null animals. In support of the antiinflam-
matory effect of Tnfip6 via the inhibition of polymor-
phonuclear (PMN) cell efflux, neutrophil invasion
during thioglycollate-induced peritonitis was 2-fold
higher in Tnfip6-deficient animals than in wild-type
animals, but was dramatically suppressed by intrave-
nous injection of recombinant murine Tnfip6.
Conclusion. Tnfip6 is a multifunctional antiin-
flammatory protein that is produced at the site of
inflammation and can be retained by the hyaluronan-
rich extracellular matrix. A major effect of Tnfip6 is the
inhibition of the extravasation of PMN cells, predomi-
nantly neutrophils, into the site of inflammation, most
likely via a CD44/hyaluronan/Tnfip6-mediated blocking
mechanism.
Tumor necrosis factor  (TNF)–induced pro-
tein 6 (Tnfip6), the secreted product of TNF-
stimulated gene 6 (TSG-6), is a member of the hyalad-
herin superfamily of hyaluronan (HA) binding proteins
(1,2). The constitutive expression of Tnfip6 is very low,
but virtually all cell types of mesenchyme origin can
produce Tnfip6 in response to proinflammatory stimuli
(2–5). Tnfip6 can be detected in large quantities in
synovial fluid samples from inflamed joints, but not in
normal healthy joints (3). Expression of Tnfip6 is up-
regulated in the inflamed synovial tissue of patients with
rheumatoid arthritis or osteoarthritis (5), indicating that
the in vivo production of this protein requires a milieu
enriched in proinflammatory mediators.
Recombinant murine Tnfip6 (rMuTnfip6) has
been shown to have a therapeutic effect on both
collagen-induced arthritis (6) and proteoglycan-induced
arthritis (PGIA) (7), and exhibits antiinflammatory and
chondroprotective properties in antigen-induced arthri-
tis (7). A chondroprotective effect could also be
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achieved in antigen-induced arthritis by cartilage-
specific constitutive expression of the Tnfip6 transgene
(8).
Tnfip6 forms a stable complex with inter--
trypsin inhibitor (II) (9,10), a major serine protease
inhibitor in serum, and potentiates the inhibitory activity
of II against plasmin. The inhibitory effect of the
Tnfip6–II complex appears to be specific for plasmin,
since no increase was observed in the inhibitory activity
against other serine proteases (10). Since plasmin is a
key activator of matrix-degrading metalloproteases, it
has been postulated that Tnfip6 exerts its antiinflamma-
tory and chondroprotective effects through the inactiva-
tion of the metalloprotease network (7,9,10).
To further elucidate the antiinflammatory prop-
erties of Tnfip6, an air-pouch model of acute inflamma-
tion was used. Injection of recombinant human Tnfip6
(rHuTnfip6) together with a stimulant (carrageenan or
zymosan) into the air pouch of mice resulted in signifi-
cant reductions in the number of emigrated neutrophils,
as compared with air pouches injected with the stimulant
only (10,11). With the use of mutant forms of rHuTn-
fip6, which has a reduced ability to bind HA via its Link
module, it has been shown that most of the antiinflam-
matory activity of Tnfip6 resides within its Link module
domain (11).
The primary objective of the present study was to
determine whether the lack of Tnfip6 increases the
predisposition of mice to develop a systemic auto-
immune form of experimentally induced arthritis such as
PGIA. For this purpose, we backcrossed Tnfip6-
deficient mice (also referred to as Tnfip6-null,
Tnfip6/, and Tnfip6-knockout mice) (originally cre-
ated in the 129Sv/C57BL/6 mixed background) into
BALB/c, a strain that exhibits genetic susceptibility to
PGIA (12–14). Tnfip6-null BALB/c mice developed ar-
thritis with greater severity than that observed in the
wild-type littermates. Moreover, the development of
PGIA in Tnfip6-deficient mice was associated with an
overwhelming influx of neutrophils into the joints, which
was rapidly followed by destruction of articular cartilage,
erosion of bone, and ankylosis. Accelerated extravasa-
tion of neutrophil granulocytes in the absence of Tnfip6
was not specific to the manifestations of arthritis, since
significantly greater influx of neutrophils was also ob-
served in thioglycollate-induced sterile peritonitis, and
we found that this could be normalized to the levels in
the wild-type littermates by exogenous addition of
rMuTnfip6.
MATERIALS AND METHODS
Generation of Tnfip6-null mice. Tnfip6 is a 20.3-kb–
long gene on mouse chromosome 2 (4). Tnfip6-deficient mice
were generated by disrupting exon 1 with the Neor-poly(A)
cassette, creating a translation stop codon at 94 bp downstream
of the translation start site in the Tnfip6 gene (15). As
described earlier, the only phenotype abnormality in Tnfip6-
deficient mice is the infertility of the Tnfip6/ females (15).
Using a marker-assisted speed-backcrossing protocol, het-
erozygous (Tnfip6/) males were mated with wild-type
BALB/c females. Males were genotyped for the presence of
the Neo gene; the heterozygous males were further tested for
genomic composition using a total of 147 simple sequence-
length polymorphic markers (16,17). Tnfip6/ males with the
most extensive BALB/c background were selected for subse-
quent backcrosses. This process was repeated 6 times until
homogeneity of the BALB/c genome was achieved, and only a
small region on chromosome 2 (harboring the Tnfip6 gene)
was a non-BALB/c locus.
The Tnfip6 mutant colony has been maintained by
intercrossing Tnfip6/ females with Tnfip6/ males, and has
been expanded to generate sufficient numbers of Tnfip6-
deficient (Tnfip6/) and wild-type (Tnfip6/) littermates for
all experiments. The animal procedures were approved by the
Animal Care and Use Committee of Rush University Medical
Center. All mice were housed under standard conditions.
Enzyme-linked immunosorbent assays (ELISAs) for
rMuTnfip6 and Tnfip6. Recombinant murine Tnfip6 was
purified on an HA-coupled EAH-Sepharose column from
supernatants of Chinese hamster ovary cells (CHO-K1; Amer-
ican Type Culture Collection, Manassas, VA) that were stable
transfected with the Lonza pEE14.1 vector (Lonza Biologics,
Slough, Berkshire, UK) containing a full-length (1,654 bp)
mouse Tnfip6 complementary DNA clone as described previ-
ously (7). Further purification was performed using reverse-
phase high-pressure liquid chromatography as described for
rHuTSG-6/rHuTNFIP6 (18). The purified product was then
lyophilized and dissolved in phosphate buffered saline (PBS)
(pH 7.4) at 1 mg/ml concentration. For in vivo treatment of
mice, the rMuTnfip6 solution was sterilized by passing it
through a 0.2-m–pore-size sterile-syringe filter.
The rat monoclonal antibody (mAb), A38, recognizing
the Link module domains of both human and mouse Tnfip6,
has been described previously (19). A sandwich ELISA was
developed using purified A38 mAb for capture, and biotinyl-
ated TSG-6–CR21 polyclonal rabbit antibody (7,8) was used
for detection of Tnfip6 in serially diluted serum samples.
Peroxidase-conjugated streptavidin (Zymed, San Francisco,
CA) followed by o-phenylenediamine and hydrogen peroxide
were used for the colorimetric detection of plate-bound Tn-
fip6, and rMuTnfip6 served as a reference standard.
Immunization with cartilage proteoglycan (PG) and
assessment of arthritis. PG was isolated from human osteoar-
thritic cartilage using a standard protocol (20), and the glycos-
aminoglycan side chains were depleted by subsequent diges-
tions of PG with endo--galactosidase and chondroitinase
ABC (Seikagaku America, Falmouth, MA) as described pre-
viously (20,21). Tnfip6/ and Tnfip6/ male and female
mice, at 10–12 weeks of age, were immunized intraperitoneally
with 100 g PG protein that was dissolved in 100 l sterile PBS
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and emulsified with 1 mg of the adjuvant dimethyldioctadecyl–
ammonium bromide (Sigma-Aldrich, St. Louis, MO) as previ-
ously described (14,21). The same doses of antigen and
adjuvant were injected on days 21 and 42, and, if necessary, on
day 63.
The paws of all immunized mice were examined twice
a week until day 21, and thereafter examined daily to record
abnormalities due to arthritic changes of the joints. The first
appearance of joint swelling was recorded as the day of the
onset of arthritis. A standard scoring system, based on the
presence of swelling and redness and having a range of 0–4 for
each paw (thus resulting in a possible maximum score of 16 for
each animal), was used for the assessment of disease severity
(12,14,22,23). Ankylosis in the peripheral joints (knee and
ankle) was defined as reduced joint mobility due to bone
deformities and periarticular stiffness.
Nonimmunized and PG-immunized arthritic wild-type
and Tnfip6/ mice were killed, and the limbs were photo-
graphed and subjected to radiographic analysis using a Hewlett
Packard Faxitron X-ray System (85 KV for 18 seconds, model
43855A; Hewlett Packard, McMinnville, OR) and high-
resolution Kodak X-Omat film (Eastman Kodak, Rochester,
NY). The limbs were then dissected, fixed, decalcified, embed-
ded in paraffin, and sectioned. Tissue sections were stained
with hematoxylin and eosin for histopathologic examination.
Measurements of antigen-specific T cell responses,
antibodies, and cytokines. During the immunization period
(once a week) and at the end of the experiments, blood
samples (for serum) were collected from the retroorbital
venous plexus of immunized mice. Spleen cells were harvested
at the end of the experiments. PG-specific antibodies in serum
were measured using ELISA, as described previously
(16,17,23). Briefly, 96-well Maxisorp plates (Nunc Interna-
tional, Hanover Park, IL) were coated with human or mouse
cartilage PG (0.1 g protein/well), the free binding sites were
blocked with 1% fat-free milk in PBS, and PG-specific anti-
bodies were measured in serially diluted serum samples of
PG-immunized mice. The total serum concentrations of anti-
PG antibodies (IgG, IgM, and IgA) were determined using
peroxidase-conjugated goat anti-mouse IgG, IgM, and IgA
antibodies (Accurate Chemical & Scientific, Westbury, NY),
and PG-specific IgG isotypes were detected with rat mAb to
mouse IgG1 or IgG2a (Zymed) as secondary reagents (16,23).
Serum antibody levels were calculated relative to the concen-
trations of the corresponding mouse IgG isotype standards (all
from Zymed) or total mouse serum Ig fractions (Sigma-
Aldrich) applied to the ELISA plates (17,23).
Antigen-specific T cell responses were determined in
quadruplicate samples of spleen cells (3  105 cells/well)
cultured in 96-well plates in the presence of 25 g PG
protein/ml culture medium. Antigen-specific interleukin-2
(IL-2) production was measured in the culture supernatants 48
hours later, using the CTLL-2 bioassay, and T cell proliferation
was assessed on day 5 by incorporation of 3H-thymidine
(16,17,20,23). The antigen-specific T cell response was ex-
pressed as the stimulation index, a ratio of incorporated
3H-thymidine (in counts per minute) in antigen-stimulated
spleen cell cultures relative to the cpm measured in nonstimu-
lated cultures. Antigen-specific production of interferon- and
IL-4 was measured in cell culture supernatants (3  106
cells/ml) on day 4 using capture ELISA methods (BD Pharm-
ingen, San Diego, CA, or R&D Systems, Minneapolis, MN) as
previously described (16,17,21). IL-1, IL-6, and TNF were
also measured in the serum samples of PG-immunized ani-
mals. Paired mAb and cytokine standards for ELISA were
obtained from BD Pharmingen or R&D Systems, and the
mouse serum amyloid A (SAA) ELISA kit was purchased from
Biosource International (Camarillo, CA).
Determination of the activities of enzymes (plasmin,
myeloperoxidase, and neutrophil elastase) in joint tissue
extracts. Nonarthritic or arthritic hind paws of the animals
were snap-frozen in liquid nitrogen and stored at 80°C. The
frozen paws were homogenized in PBS containing 0.5%
hexadecyl–trimethylammonium bromide, 0.1% sodium dode-
cyl sulfate, and 1% Nonidet P40 (all purchased from Sigma-
Aldrich), sonicated on ice, and cleared by centrifugation. An
assay for plasmin activity was performed using the chromo-
genic substrate tosyl-Gly-Pro-Lys-4-nitranilide acetate (Chro-
mozym PL; Roche, Mannheim, Germany) (10,11).
The accumulation of neutrophils in inflamed paws was
monitored by assaying myeloperoxidase activity in the super-
natants of paw extracts, with hydrogen peroxide as a substrate
and 3,3,5,5-tetramethylbenzidine as a chromogenic reagent
(24). Neutrophil elastase activity was measured using the
substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-pNA (Elastin
Products, Owensville, MO) (25), in accordance with the man-
ufacturer’s instruction. The results of all enzyme assays were
normalized to the total protein concentration of the paw
extracts, determined by the bicinchoninic acid method (Pierce,
Rockford, IL). Myeloperoxidase activity was expressed as the
equivalent of the neutrophil numbers found in the peripheral
blood of normal BALB/c mice. Colorimetric reactions of
serially diluted, purified neutrophil elastase (Elastin Products)
and plasmin (Sigma-Adrich) with the specific substrates served
as standards for calculation of the activities of the respective
enzymes in the tissue extracts.
Neutrophil extravasation in thioglycollate-induced
peritonitis in wild-type and Tnfip6-deficient mice, with or
without treatment with rMuTnfip6. Peritonitis was induced by
intraperitoneal injection of 0.5 ml of 4% sterile thioglycollate
(Becton-Dickinson, Sparks, MD) as described previously
(26,27). Peritoneal lavage was performed 0, 2, 4, 6, 8, 12, 24, 48,
72, and 96 hours after thioglycollate administration. Ten
milliliters of ice-cold PBS was injected into the peritoneal
cavity of each mouse, and the abdomen was massaged for 2
minutes, after which 4 ml of the lavage fluid was collected.
Leukocytes in the fluid samples were stained with 0.2%
crystal violet (Sigma-Aldrich) in 10% acetic acid, and then
counted in a hemocytometer; total cell numbers were calcu-
lated for the 10-ml volume of PBS injected intraperitoneally.
Leukocyte differential counts were determined in Giemsa-
stained smears of the cell pellets. The cellular composition of
the peritoneal lavage fluid was confirmed by flow cytometry
using fluorochrome-labeled mAb to CD45/B220 (B cells), CD3
(T cells), and Gr-1 (granulocytes) (all from BD Pharmingen)
and mAb F4/80 to macrophages/monocytes (purchased from
Serotec, Raleigh, NC) (21). Separate groups of wild-type and
Tnfip6-deficient mice were injected intravenously with 30 g
rMuTnfip6 in 60 l PBS 20 minutes before intraperitoneal
thioglycollate administration, and the effect of rMuTnfip6
treatment on the cell counts, as well as the types of recruited
leukocytes in the peritoneal lavage fluid, were determined at 0,
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2, 4, 8, 12, 24, and 48 hours after thioglycollate injection, as
described above.
Statistical analysis. Statistical analysis was performed
using SPSS software, version 7.5 (SPSS, Chicago, IL). The
Mann-Whitney and Wilcoxon tests, or the Student’s t-test,
were used for comparisons between wild-type and Tnfip6-
deficient mice. The level of significance was set at a P value less
than 0.05.
RESULTS
Increased incidence and severity of PGIA in
Tnfip6-deficient BALB/c mice. Tnfip6-deficient mice
and wild-type littermates were monitored for the devel-
opment of arthritis for 11–15 weeks after the primary
immunization with PG. Clinical signs of arthritis first
appeared between experimental days 47 and 49 (5–7
days after the third PG injection) in both groups (Figure
1). The incidence of PGIA increased more rapidly in the
Tnfip6-null mice than in the wild-type mice, and by day
71 (8 days after the fourth PG injection), all of the
mutant mice were arthritic, whereas the incidence of
arthritis was only 62% in the wild-type group at this time
point (Figure 1A). The disease progressed more rapidly
and the arthritic limbs exhibited higher inflammation
scores in the Tnfip6/ mice than in the wild-type
littermates throughout the entire observation period
(Figure 1B). However, there were no differences in
disease onset, severity, or incidence between the males
and females in either group.
Gross morphology, results of histopathology, and
radiographic appearance of the peripheral joints. His-
topathologic examination of the hind paw joint sections
prepared at the early phase of joint inflammation (2 days
after onset) revealed more extensive infiltration of the
synovial lining by polymorphonuclear (PMN) cells
(mostly neutrophils) and a much higher number of
neutrophils in the joint exudates of Tnfip6-null mice
compared with wild-type mice (Figures 2A and B). On
day 10 after the onset of PGIA, the histologic assessment
showed evidence of inflammatory damage in only the
upper zone of articular cartilage in the joints of wild-
type mice (Figure 2C), whereas the cartilage had been
completely destroyed in the joints of Tnfip6-deficient
mice at this time point (Figure 2D).
As expected from the results of our earlier stud-
ies that demonstrated a chondroprotective effect of
intraarticularly injected rMuTnfip6 (7), the articular
cartilage was not protected from the inflammatory at-
tack in mice lacking endogenous Tnfip6. There was no
evidence of cartilage loss in the absence of inflammation
in Tnfip6-knockout mice (e.g., in the nonarthritic joints
of PG-immunized animals [results not shown]), indicat-
ing that cartilage destruction did not occur spontane-
ously, but was triggered by the inflammatory process.
Only 10 days after the first appearance of joint swelling,
Tnfip6-deficient animals showed histologic signs of re-
active fibrosis at the joint margins (Figure 2D), a
presumed repair response that usually occurs in wild-
type BALB/c mice at a late stage of chronic PGIA, i.e.,
several weeks after the onset of arthritis (14).
As a result of the rapid progression and increased
Figure 1. Incidence and severity of proteoglycan-induced arthritis
(PGIA) in tumor necrosis factor –induced protein 6 (Tnfip6)–
deficient (Tnfip6/) and wild-type (Tnfip6/) BALB/c mice. Arthri-
tis was first detected on day 49 in both groups, i.e., 7 days after the
third intraperitoneal immunization with cartilage proteoglycan, but
both the incidence (A) and severity (B) of arthritis increased faster and
remained higher during the experimental period in the Tnfip6-
deficient BALB/c mice than in their wild-type littermates. Bars show
the mean and SEM. Thirty-five Tnfip6/ and 32 wild-type (Tnfip6/)
mice were used in 3 independent immunization experiments.
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severity of PGIA in Tnfip6-deficient animals, massive
ankylosis developed 5–7 weeks earlier than in the wild-
type littermates. The degree of ankylosis and the extent
of joint deformities in Tnfip6-knockout mice far ex-
ceeded those ever observed in wild-type BALB/c mice
(see Figures 3D and G). The extremely aggressive
character of PGIA in Tnfip6-deficient animals was re-
flected in the high degree of pathologic changes that
occurred in the joint shape and in the structure and
density of the subchondral bone (e.g., in the metatarso-
phalangeal joints), as revealed by macroscopic inspec-
tion, histology, and radiographic analysis, respectively
(Figure 3).
Immune responses and cytokine profiles in PG-
immunized Tnfip6-deficient and wild-type BALB/c mice.
PGIA is a systemic disease initiated and governed by
autoreactive T cell responses and autoantibodies against
the mouse (self) cartilage PG (13,14,20). Therefore, it
was important to determine whether the dramatic dif-
ferences in arthritis severity and in the rate of disease
progression between wild-type and Tnfip6-deficient
mice (as shown in Figures 1–3) were associated with a
more aggressive autoimmune response and/or the pro-
duction of related cytokines in BALB/c mice lacking
Tnfip6. T and B cell responses and cytokine levels were
examined at 3 different time points during disease
induction and development: in the period prior to onset
of arthritis (a few days after the third antigen injection)
when the animals were still asymptomatic (Figure 1), at
the acute phase (2–3 days after the onset of arthritis),
and during the chronic phase (4 weeks after the onset
of arthritis). We did not find significant differences
Figure 2. Histopathology of PGIA in wild-type and Tnfip6-deficient BALB/c mice 2 days (A and B) and
10 days (C and D) after the onset of arthritis affecting the metatarsophalangeal (MTP) joints of the hind
paws. Massive neutrophil invasion dominates the histopathologic picture at the very early stage, and this
is notably more pronounced in the synovial lining and joint cavity of the Tnfip6-deficient animal (B)
(arrows) than in that of a wild-type littermate (A) (arrows). Insets show high-magnification views of
neutrophils at the interface of the synovium and joint cavity. Ten days after the onset of PGIA, cartilage
and bone damage are evident in both wild-type and Tnfip6/ joints (C and D); however, the articular
cartilage has already been completely destroyed in the MTP joint of the Tnfip6-deficient mouse (D). The
joint of the Tnfip6/ mouse also shows histologic evidence of bone erosion and subsequent replacement
of bone by a fibrotic tissue (D) (arrow) (compare with arrow in C). (Hematoxylin and eosin stained.) See
Figure 1 for other definitions.
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between the wild-type and Tnfip6-deficient animals in
PG-specific T or B cell responses at any of those time
points (test results on day 81 are shown in Figure 4).
Stimulation of T cells (Figure 4A) and production of
antigen-specific Th1- and Th2-type cytokines (Figure
4B), heteroantibodies (against human PG) (Figure 4C),
and autoantibodies (against mouse PG) (Figure 4D)
were all comparable in the 2 genotypes of mice.
Serum levels of the proinflammatory cytokines
IL-1 (Figure 5A) and TNF (Figure 5B) were also
similar between the Tnfip6-null and wild-type animals.
However, serum concentrations of IL-6 (Figure 5C) and
the acute-phase reactant SAA (Figure 5D) were signif-
icantly higher in the Tnfip6-deficient mice than in the
wild-type mice at the acute phase of PGIA.
Enzyme activities in the joint tissues of Tnfip6-
deficient and wild-type BALB/c mice. Tnfip6 binds II, a
powerful serine protease inhibitor in serum, and this
interaction has been shown to potentiate the inhibitory
effect of II on plasmin (9). Thus, plasmin activity was
expected to be elevated in the joints with inflammation.
Some plasmin activity was detected in the total extracts
Figure 3. Macroscopic, radiographic, and histopathologic images of the hind paws of nonimmunized
(A–C) and proteoglycan-immunized wild-type (D–F) and Tnfip6-deficient (G–I) BALB/c mice with
arthritis. Macroscopic images, radiographs, and histologic sections were prepared on day 105 of the
experiment (8 weeks after the onset of the inflammation). The same paws are shown in the
corresponding macroscopic pictures, radiographic images, and histologic sections. Joint deformities and
cartilage and bone erosions are more pronounced in the Tnfip6-deficient mouse (G–I) than in the
wild-type mouse (D–F), although the first clinical symptoms (redness and swelling of the paw) appeared
on the same day in both mice. Hematoxylin and eosin–stained histologic sections show the second
metatarsophalangeal joints (MTPJ) of the corresponding paws (C, F, and I). White arrows and dotted
lines in F and I indicate invasion of the bone by pannus-like soft tissue. See Figure 1 for other definitions.
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of nonarthritic joints (Figure 6A), which was most likely
the result of an association with the normal metabolic
turnover of matrix components. After the development
of arthritis, however, plasmin activity was almost 2-fold
higher in the joint tissues of mice lacking Tnfip6,
whereas only a moderate increase (50%) was found in
the paws of wild-type animals (Figure 6A).
As an indicator of neutrophil invasion, the activ-
ity of the neutrophil granulocyte–specific enzyme myelo-
peroxidase was measured in the total extracts of nonar-
thritic and arthritic paws of wild-type and Tnfip6-
deficient animals (Figure 6B). Consistent with the
histopathologic findings, myeloperoxidase activity was
significantly elevated in the inflamed paws of Tnfip6-null
mice when compared with the arthritic paws of wild-type
animals (Figure 6B).
We also determined the activity of the neutrophil
elastase, which could be involved in tissue damage upon
release from locally activated neutrophils. The activity of
this enzyme was significantly higher in the arthritic paws
of Tnfip6-knockout mice compared with that in the paws
of the wild-type mice (Figure 6C), and this increase was
proportional to the extent of myeloperoxidase activity
(as measured by neutrophil number) in Tnfip6-null joints
(Figure 6B).
Neutrophil influx into the peritoneal cavity dur-
ing thioglycollate-induced peritonitis in wild-type and
Tnfip6-deficient mice, and the effect of rMuTnfip6 treat-
ment. The histopathologic examination of the joints
(Figure 2) and the results of enzyme (myeloperoxidase
and neutrophil elastase) assays (Figure 6) suggested that
Tnfip6 deficiency could selectively facilitate the influx of
neutrophil granulocytes into the site of inflammation.
This was consistent with the observations of earlier
studies in which it was reported that systemic or local
administration of rHuTnfip6 inhibited neutrophil migra-
tion into nonspecific irritant- or cytokine-stimulated air
Figure 4. Summary of immune responses in wild-type (Tnfip6/)
and tumor necrosis factor –induced protein 6 (Tnfip6)–deficient
(Tnfip6/) mice. Antigen (proteoglycan [PG])–specific T cell prolif-
eration and interleukin-2 (IL-2) production (A), and Th1-type cytokine
interferon- (IFN) and Th2-type IL-4 (B) were measured in super-
natants of PG-stimulated spleen cell cultures from arthritic mice.
PG-specific antibodies against the immunizing human PG (C) and
autoantibodies against mouse cartilage PG (D) (both the Th2-
supported IgG1 and Th1-supported IgG2a isotypes) were measured in
the sera of animals at the end of the experiments. Bars show the mean
and SEM in 35 Tnfip6/mice and 32 wild-type mice (same animals as
shown in Figure 1).
Figure 5. Serum concentrations of proinflammatory cytokines IL-1
(A), tumor necrosis factor  (TNF) (B), and IL-6 (C) and the
acute-phase protein serum amyloid A (SAA) (D). Cytokines were
measured in serum samples of wild-type and Tnfip6-deficient BALB/c
mice during the acute phase (on day 53) and chronic phase (on day 81)
of proteoglycan-induced arthritis. Sera were collected from the retro-
orbital venous plexus of arthritic animals on day 53 (n  15 in each
group) or at the end of the experiments (day 81; n 35 Tnfip6/mice
and n  32 wild-type mice, as in Figures 1 and 4). Bars show the mean
and SEM.   P  0.01 versus wild-type mice. See Figure 4 for other
definitions.
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pouches in mice (10,11). Since a method for the accurate
measurement of leukocyte infiltration in the small peri-
pheral joints of mice is not available, we used
thioglycollate-induced sterile peritonitis to compare
neutrophil accumulation in wild-type and Tnfip6-
deficient mice, and to quantitatively determine the effect
of exogenous Tnfip6 on PMN cell extravasation.
This model is characterized by the influx of
predominantly neutrophil granulocytes and monocytes/
macrophages into the peritoneal cavity (26,27), from
which these cells can be easily isolated. Indeed, the
peritoneal exudate (lavage fluid) was dominated by
PMN cells between 4 hours and 48 hours (showing a
peak of influx at 24 hours) after injection of thioglycol-
late, whereas the number of mononuclear cells was
relatively low and remained nearly constant during the
96-hour observation period in both genotypes of mice
(Figure 7). At each time point between 4 hours and 96
hours, 2–3 times more neutrophils migrated into the
peritoneal cavities of Tnfip6-deficient animals than into
the cavities of wild-type mice (Figure 7). A single dose
(30 g) of rMuTnfip6, injected intravenously 20 minutes
before the thioglycollate challenge, reduced the neutro-
phil numbers in the peritoneal lavage fluid by at least
50% in both wild-type and Tnfip6-deficient mice (Figure
7, front columns), and this inhibitory effect on neutro-
phil influx was still detectable at 48 hours after thiogly-
collate administration to rMuTnfip6-injected animals.
Figure 6. Activities of myeloperoxidase and 2 serine proteases measured in tissue extracts of the nonarthritic and
inflamed paws of Tnfip6-deficient and wild-type BALB/c mice with proteoglycan-induced arthritis. Tissue
extracts were prepared separately from the noninflamed and the inflamed paws of the same animal 2–4 days after
the onset of arthritis. Arthritis scores of the inflamed paws ranged between 1 and 4 by this time point, and
therefore equal numbers (n  12) of arthritic paws with highly comparable individual arthritis scores were
selected for these assays. The overall arthritis score was a mean 	 SEM 3.0 	 0.73 in the wild-type mice and
2.91 	 0.71 in the Tnfip6-deficient group. Enzyme activities were normalized to protein content. Myeloperoxi-
dase activity (B) is expressed as the enzyme activity relative to the numbers of polymorphonuclear (PMN) cells
(neutrophils) measured in peripheral blood of normal BALB/c mice, whereas the activity of plasmin (A) and
neutrophil elastase (C) is expressed in units, using the activity of the corresponding purified enzyme as a
reference.   P  0.05 versus wild-type mice. See Figure 4 for other definitions.
Figure 7. Neutrophil extravasation in thioglycollate-induced peritoni-
tis in wild-type and Tnfip6-deficient mice, with or without treatment
with recombinant murine Tnfip6 (rMuTnfip6). Columns at the back
represent total cell numbers in the peritoneal cavity after 0.5 ml of 4%
thioglycollate injection, in which the upper areas correspond to
neutrophil (polymorphonuclear [PMN]) cell number and the bottom
areas are representative of the macrophage (monocyte [Mo]) numbers
in the same samples. Columns at the front show the effect of
rMuTnfip6 (30 g injected intravenously 20 minutes before the thiogly-
collate challenge) on the peritoneal cell number. This intravenously
injected rMuTnfip6, however, showed a rapid decline in the serum and
was no longer detectable by enzyme-linked immunosorbent assay at
25–30 minutes after the injection (results not shown). Cells were counted
in aliquots of the peritoneal lavage fluid, and differential counts were
determined in May-Gru¨nwald– and Giemsa-stained smears of the peri-
toneal lavage fluid and confirmed by flow cytometry. The proportion
of lymphocytes (CD3 and CD45/B220 cells) was fewer than 2% of
the total cell number at each time point (results not shown). Bars show
the mean and SEM. See Figure 4 for other definitions.
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DISCUSSION
In this study, we demonstrate that Tnfip6 defi-
ciency increases the severity and accelerates the progres-
sion of PGIA in BALB/c mice. Wild-type and Tnfip6-
deficient animals mount similar autoimmune responses
(including antigen-specific T cell reactions, a balance
between the Th1 and Th2 response, and antibody pro-
duction) following immunization with cartilage PG.
However, at the early (initial) phase of arthritis, there is
a striking increase in the number of PMN cells in the
synovium and joint exudate in mice lacking Tnfip6.
Inflammatory destruction of the articular cartilage, ero-
sion of bone, and joint deformities develop earlier and
are more extensive in Tnfip6-null mice than in wild-type
BALB/c mice. Serum markers of inflammation, includ-
ing IL-6 and SAA, are also significantly elevated in
Tnfip6-deficient mice during the acute phase of PGIA.
Thus, although treatment of mice with recombinant
Tnfip6 has been shown to exert a therapeutic effect in
various forms of experimentally induced inflammation
(6,7,10,11), the lack of endogenous Tnfip6 increases the
severity of inflammation.
In vivo expression of TSG-6/Tnfip6 has been
associated with inflammatory arthritis (3,5), but the
protein is produced in a variety of cells exposed to
proinflammatory stimuli in vitro (2,28,29), and also in a
physiologic process such as matrix formation around the
cumulus cell–oocyte complex (30). In fact, the relation-
ship between impaired cumulus cell–oocyte matrix as-
sembly and female sterility in Tnfip6-knockout mice
reveals an essential role for this protein in the formation
of crosslinked HA fibers around the oocyte that is
necessary for the expansion of cumulus matrix and
subsequent oocyte fertilization (15).
The antiinflammatory properties of Tnfip6 have
been mainly attributed to its ability to potentiate the
antiplasmin activity of II upon association with this
protease inhibitor, leading to the subsequent down-
regulation of the activity of a number of matrix-
degrading proteases (7–10). However, a recent study
(11) found that the isolated Link module domain of
Tnfip6, which lacks the ability to associate with II,
could still inhibit the influx of neutrophils to the site of
inflammation. This observation suggests that Tnfip6
might exert antiinflammatory effects in an II-
independent manner.
Although we have found elevated plasmin activ-
ity in tissue extracts prepared from the arthritic joints of
Tnfip6-null mice, the most striking effects of Tnfip6
deficiency are the increases in the number of neutrophils
and the activity of neutrophil-derived enzymes in the
affected joints. Accelerated destruction of the articular
cartilage and rapid progression of joint deformities in
Tnfip6-null mice, therefore, could be associated with
both enhanced neutrophil invasion and insufficient pro-
tection of cartilage matrix components from plasmin-
activated proteases. We have shown that influx of PMN
cells into the peritoneal cavity is also enhanced in
Tnfip6-null mice in response to local injection of thio-
glycollate, indicating that neutrophil egress is facilitated
in the absence of Tnfip6, independently of the site or
type of inflammation.
Tnfip6 is an HA binding protein, and HA is
known to support the CD44-dependent rolling of leuko-
cytes (31–34), the first step toward their extravasation
(35). It is a natural question, therefore, whether Tnfip6
is somehow involved in the adhesive interaction between
CD44 and HA. A recent study by our group (36)
demonstrated that, indeed, Tnfip6 modulates the inter-
action between HA and cell-surface CD44. Binding of
HA to the cell surface is enhanced when CD44-positive
cells are exposed to preformed Tnfip6–HA complexes,
and HA in these complexes is recognized by cells
expressing inactive CD44 that does not bind HA consti-
tutively, i.e., without induction (36). Cells roll more
readily on immobilized substrates consisting of
Tnfip6–HA complexes as compared with substrates of
HA alone, but firm adhesion to HA is not significantly
facilitated in the presence of Tnfip6. Importantly, cell-
surface–bound Tnfip6–HA complexes prevent CD44-
mediated leukocyte adhesion to HA (36). Although
these in vitro observations do not provide a full expla-
nation for the in vivo effects of Tnfip6 (or the lack
thereof), intravital videomicroscopy has currently re-
vealed some important differences between Tnfip6-
deficient and rMuTnfip6-treated mice. As shown for
thioglycollate-induced peritonitis in this study, intrave-
nously injected rMuTnfip6 almost completely abolishes
leukocyte extravasation in TNF-induced local ear in-
flammation (see ref. 37 and Sza´nto´ S, et al: unpublished
observations).
The results of these in vivo experiments suggest
that Tnfip6 plays a role in the control of leukocyte influx
into arthritic joints (most likely via interference with
CD44/HA-mediated adhesion events), and is involved
locally in the protection of cartilage matrix from proteo-
lytic damage through complex formation with the serine
protease inhibitor II (7,8). The most important mes-
sage of our in vitro and in vivo studies is that Tnfip6 can
directly modulate cell adhesion (36,37), PMN cell ex-
travasation (Figures 2 and 7), and perhaps also, the
3020 SZA´NTO´ ET AL
production of proinflammatory mediators such as IL-6
(Figure 5C). Thus, the suppressive effects of Tnfip6 on
arthritis (6,7) are exerted through more than one mech-
anism. The effects of Tnfip6 are not restricted to joints
(and arthritis), since this protein seems to inhibit other
types of inflammation as well. Inhibition of inflamma-
tory leukocyte (neutrophil) influx into the joint could be
the most important function of Tnfip6 in arthritis sup-
pression, but its interaction with II might provide the
cartilage matrix an enhanced protection from proteolytic
damage. Therefore, in inflammatory/rheumatoid arthri-
tis, recombinant Tnfip6 holds promise as a therapeutic
agent.
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